The need for more effective lung cancer treatments is paramount, as the disease remains a leading cause of cancer deaths in the United States. New findings by a research team from the Stony Brook Cancer Center highlight a novel therapeutic shown to be highly effective in reducing non-small cell lung cancer (NSCLC) tumors and appearing to halt drug resistance in a laboratory model.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗